Immunotherapy – 2067. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study by unknown
MEETING ABSTRACT Open Access
Immunotherapy – 2067. FEL d 1 peptide antigen
desensitization safety and efficacy in a double-
blind, placebo-controlled environmental
exposure chamber study
Roderick Peter Hafner1*, Piyush Patel2, Annemarie Salapatek3, Paul Laidler1, Mark Larché4, Deepen Patel3
From 2nd WAO International Scientific Conference (WISC 2012)
Hyderabad, India. 6-9 December 2012
Background
Allergic rhinoconjunctivitis is an increasing problem
worldwide with significant impact on quality of life and
productivity. Sensitivity to cats accounts for 10-15% of the
disease burden. Previous immunotherapy studies with two
27aa peptides were unsuccessful as a result of early and
late phase responses. Cat Peptide Antigen Desensitisation
(Cat-PAD) is a mixture of seven T-cell epitopes (13-17aa)
derived from Fel d1. This study evaluated safety and rela-
tionship between dose, dosing regimen and symptom
scores in cat allergic subjects with rhinoconjunctivitis 17-
21weeks(wk) after starting treatment using a standardized
allergen challenge in an Environmental Exposure Chamber
(EEC).
Methods
In a multicentre, double-blind, placebo-controlled clinical
trial, subjects attended an EEC, before and after treatment.
121 subjects were randomised to one of four treatment
regimens (Cat-PAD: 4x3nmol 2wk apart, 4x6nmol 2wk
apart, 4x3nmol 4wk apart, 8x3nmol 2wk apart) or placebo.
Clinical efficacy was assessed by measurement of changes
in Total Rhinoconjunctivitis Symptom Score (TRSS) during
EEC visits. Safety was assessed by observing subjects in the
clinic for 1 hour on each dosing day and capturing adverse
events (AE) by direct questioning of subjects at every visit.
Results
There were no Serious Adverse Events. Frequencies of all
Treatment Emergent Adverse Events (TEAE) in the Cat-
PAD treatment arms were less than in the Placebo cohort
with the exception of the 6nmol cohort which trended
slightly higher. Analysis of the respiratory system TEAEs
showed no evidence of any safety signal after treatment
with Cat-PAD. Respiratory system TEAEs, including
asthma, dyspnoea and wheezing, occurred at a low fre-
quency in both active and placebo groups, with no obvious
difference between the groups. Treatment with Cat-PAD
showed greater efficacy when dosed over 12-14wk than
when dosed over 6wk. 8x3nmol dose showed a statistically
significant reduction in symptoms vs placebo (p < 0.05) in
subjects who attended the main centre for all their visits.
The 6nmol dose showed a trend to be superior to the
3nmol dose, albeit tested in a sub-optimal regimen.
Conclusions
Cat-PAD was safe and well tolerated and improved TRSS.
Potential for greater treatment benefits by using a higher
dose over 12-14wk should be evaluated in future studies.
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